Navigation Links
PharmAthene Reports First Quarter 2008 Financial Results
Date:5/13/2008

revent and treat organophosphorous nerve agent poisoning; RypVax(TM), a recombinant dual antigen plague vaccine; and finally, third generation rPA anthrax vaccine technology. For more information about PharmAthene, please visit http://www.PharmAthene.com.

Statement on Cautionary Factors

Except for the historical information presented herein, matters described in this press release may constitute forward-looking statements which are within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by words such as "believe," "expect," "anticipate," "plan," "potential," "continue" or similar expressions and relate to, among other things, the ability of the Company to achieve milestones or to create value for its stockholders. Forward-looking statements also include the assumptions underlying or relating to any of the foregoing statements. Such forward-looking statements are based upon current expectations or beliefs of management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements including, but not limited to, risks associated with obtaining regulatory approvals, unforeseen technical difficulties, dependencies on certain customers or products, market acceptance and competition, ability to receive grant and contract revenue and procurement funding, ability to identify any additional strategic acquisitions or other opportunities to accelerate growth, cash at the end of the year, as well as other risks described in the Company's filings with the Securities and Exchange Commission, in conference calls and in other communications.

PharmAthene Inc.

Consolidated Balance Sheets

ASSETS


'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. PharmAthene to Host First Quarter 2008 Conference Call and Webcast on Tuesday, May 13, 2008
2. PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
3. PharmAthene Reports Year-End 2007 Financial Results
4. Department of Defense Awards $5.8 Million Contract Modification Providing Additional Funding for PharmAthenes Protexia(R) Program
5. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
6. PharmAthene to Delay Release of Full Year 2007 Financial Results
7. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
10. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
11. PharmAthene to Present at the BIO CEO & Investor Conference 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... NEW YORK , Aug. ... announces that a new market ... its catalogue: Whole ... (Systems, Kits (Library Preparation, Target ... Technology (Sequencing by Synthesis), by ...
(Date:8/28/2014)... 28, 2014  Armetheon, Inc. ( www.armetheon.com ), ... to late-stage cardiovascular drug candidates, today announced that ... round of financing. The Series A round was ... with participation from investors that included Atheneos Capital ... Larry Hsu , the founder of Impax ...
(Date:8/28/2014)... PrimeSource Building Products, Inc., a ... SoundConnect to support their communication needs with ... web conferencing platform GlobalMeet powered by SoundConnect. The ... SoundConnect delivers award winning “results driven” business ... will be utilizing GlobalMeet powered by SoundConnect ...
(Date:8/27/2014)... BOSTON , Aug. 27, 2014 Rhythm, ... diseases and genetic deficiencies that result in metabolic disorders, ... on Form S-1 with the U.S. Securities and Exchange ... of shares of its common stock. The number of ... the offering have not yet been determined. ...
Breaking Biology Technology:Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3PrimeSource Chooses SoundConnect as Collaboration Provider 2Rhythm Files Registration Statement for Proposed Initial Public Offering 2
... , , Additions to the Human Protein ... 6,100 antibodies powered by Atlas Antibodies , , ST. ... today announced the release of over 2,300 antibody additions to ... www.sigma.com/prestige ), bringing the total number of highly ...
... Austria, June 23 MIG Fonds and AFFiRiS AG are,this ... Award,competition, hosted by the industry magazine Boerse-Express and Junge,Industrie. The ... the Austrian biotechnology company as well as a euro,430 million ... Last Tuesday MIG Fonds and AFFiRiS AG were awarded ...
... June 22 Trubion Pharmaceuticals, Inc. (Nasdaq: ... of Wyeth (NYSE: WYE ), has exercised ... with Trubion to extend the research period for an ... terms of the research period extension, Wyeth,s obligations to ...
Cached Biology Technology:Sigma-Aldrich and Atlas Antibodies Announce 2,300 New, Highly Validated Prestige Antibodies(RM) 2Sigma-Aldrich and Atlas Antibodies Announce 2,300 New, Highly Validated Prestige Antibodies(RM) 3Sigma-Aldrich and Atlas Antibodies Announce 2,300 New, Highly Validated Prestige Antibodies(RM) 4AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS 2AFFiRiS AG: 1st Place in Venture Capital & Private Equity Awards for MIG Fonds and AFFiRiS 3Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration 2Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration 3
(Date:8/28/2014)... (Maximizing Access to Research Careers) Program has announced the ... Genetics from October 18 22, 2014 in San ... the entry of students, post doctorates and scientists from ... community and to encourage the participation of young scientists ... year MARC conferred 16 awards totaling $29,600., The FASEB ...
(Date:8/28/2014)... peer groups and clinicians is critical to the ... University of Georgia research. , A qualitative study ... determined that role models for successful breastfeeding help ... , "Mothers who received that support are more ... co-author Alex Anderson, an associate professor in the ...
(Date:8/28/2014)... to Research Careers) Program has announced the travel ... Medicine,s Conference on Integrative Physiology of Exercise from ... awards are meant to promote the entry of ... into the mainstream of the basic science community ... at the American College of Sports Medicine,s Conference ...
Breaking Biology News(10 mins):Breastfeeding study shows need for effective peer counseling programs 2
... conditions leading to heart attacks and strokes are treated ... or lung, but now turn out to involve some ... This in turn provides clues to more effective therapies ... in these distinct fields to come together. The seeds ...
... DC Although Americans are becoming increasingly aware of ... A in some baby bottles and lead in some ... with personal chemical exposure and related adverse health effects, ... Journal of Health and Social Behavior . ...
... the Nov. 20 edition of Heredity could ... evolution of separate sexes, a theory that holds that ... stages are not completely understood because the majority of ... state too long ago for scientists to observe the ...
Cached Biology News:Mechanisms of cardiovascular disease and cancer give clues to new therapies 2Mechanisms of cardiovascular disease and cancer give clues to new therapies 3Pollution at home lurks unrecognized, instead attributed to large-scale environmental disasters 2Two from one: Pitt research maps out evolution of genders from hermaphroditic ancestors 2
Rabbit polyclonal to CAMK 1D beta ( Abpromise for all tested applications). entrezGeneID: 57118 SwissProtID: Q5SQQ7...
Request Info...
Goat polyclonal to HNF4 ( Abpromise for all tested applications). Antigen: Synthetic peptide: RLSKTLVDMDMADY (Human) N terminal. Entrez GeneID: 3172 Swiss Protein ID: P41235...
Goat polyclonal to SART1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: GSSKKHRGEKEAA, corresponding to N terminal amino acids 2-14 of Human SART1. Entrez Gene ID: 909...
Biology Products: